Last edition
News about "MHRA"
Glenmark Secures Exclusive Multi-Region Rights to Aumolertinib from Hansoh Pharma
Glenmark has entered into an exclusive licensing agreement with Hansoh Pharma to commercialise aumolertinib, a third-generation EGFR-TKI approved by the MHRA and China’s NMPA, across multiple international markets, reinforcing the company’s oncology portfolio and expansion strategy in high-growth regions.
MHRA | 17/12/2025 | By News Bureau
Relonchem Gets MHRA Nod for Exemestane 25 mg Tablets
Exemestane by Relonchem, a subsidiary of Markans Pharma, is an aromatase inhibitor used in the treatment of hormone-dependent breast cancer in postmenopausal women. The approval marks another milestone in Marksans Pharma’s strategy to expand its oncology portfolio and strengthen its presence in the UK and European markets.
MHRA | 05/11/2025 | By Dineshwori | 139
Sitryx receives FDA clearance of IND application for SYX-5219 for the treatment of atopic dermatitis
Sitryx’s SYX-5219 is a first-in-class, oral, disease-modifying, anti-inflammatory therapy, targeting pyruvate kinase M2 (PKM2), a critical enzyme that regulates cell metabolism.
MHRA | 04/10/2025 | By Dineshwori | 153
IPA Set to Host 8th Global Pharmaceutical Quality Summit, Focusing on 'Patient Centricity - A New Manufacturing and Quality Paradigm
MHRA | 14/06/2023 | By Sudeep Soparkar | 888
Celadon Pharma's UK-based facility bags GMP registration by MHRA
Celadon's medicinal cannabis product will be supplied in oil form as an API
MHRA | 17/01/2023 | By Sudeep Soparkar | 798
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy